How to Buy Incyte Stock
Incyte Corp
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally.
Incyte stock last closed at $102.60, up 1.66% from the previous day, and has increased 38.42% in one year. It has overperformed other stocks in the Biotechnology industry by 0.69 percentage points. Incyte stock is currently +91.56% from its 52-week low of $53.56, and -8.63% from its 52-week high of $112.29.
At the moment, there are 196.32M shares of INCY outstanding. The market capitalization of INCY is $20.14B. In the past 24 hours, 1.92M INCY shares were traded.
How to Buy Incyte Stock
Not sure how to invest in Incyte stock? Here's how.
- Figure out where to buy Incyte stock: You need to choose a stock brokerage, but don't worry - we've tried dozens of stock brokerages and apps to help you decide where to buy Incyte stock.
- Sign up for your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've selected.
- Deposit funds into your brokerage account: Pick your payment method and add your details.
- Analyze Incyte stock: The Incyte ticker symbol is INCY. Is Incyte stock a good investment? Should you buy shares of INCY? How do INCY's underlying business fundamentals look? Do top analysts think Incyte is a good buy? Why has INCY's stock price moved recently? (Hint: Our stock market research tools can help you understand if INCY is a good stock to buy).
- Execute your INCY purchase: Decide if you will purchase INCY shares at the current market price or use a limit order to buy INCY stock at a particular price.
- Monitor your INCY position: Create a watchlist to monitor your new investment in Incyte stock.
Step 1: Figure out where to buy Incyte stock
You will need an online brokerage account in order to access the NASDAQ market and buy INCY shares.
Our recommended brokerage: eToro
Based on our analysis, eToro is the best brokerage. eToro gives you:
- You can invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
- Access to world markets: From Tech to Utilities, New York to Shanghai (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's leading exchanges.
- Social investing: eToro offers a community with more than 20 million users worldwide. Talk to, learn from, and copy the unique crypto portfolios of other investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your purchase of stock by creating an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Sign up for your brokerage account
Now that you've selected the best brokerage, you'll need to fill out some personal details so you can invest in INCY today.
How to Create a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal details to start a new trading account.
- Send your info by pressing the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your brokerage account
Now that you have finished signing up on investing apps, you can securely and quickly fund your account:
Check out this video walkthrough for more details transferring funds into your new brokerage account.
Step 4: Analyze Incyte stock
Once you have decided on the best place to buy Incyte stock, it's crucial to evaluate their stock before you invest, so you can wrap your head around the risk as well as the upside.
Incyte quick stats
Fundamentals of INCY
WallStreetZen was created to help part-time investors do more in-depth fundamental analysis in less time.
You can see all of the due diligence checks on INCY's stock page.
What is the fair value of INCY stock?
Investors use a variety of different financial metrics, analyses, models, and charts to gauge INCY's intrinsic value.
Using relative valuations measures:
- INCY could be undervalued based on its P/E ratio of 16.99x, relative to Biotechnology industry P/E ratio of 191.13x
- INCY could be undervalued based on its P/B ratio of 4.33x, relative to Biotechnology industry P/B ratio of 5.17x
- INCY may be undervalued based on its PEG ratio of 0.9x
You can do additional valuation analysis on INCY's stock here.
INCY Financial Health Summary
Passed Health Checks:
- Total INCY debt is lower than 5 years ago, relative to shareholder equity.
- There are more short-term assets than short-term liabilities on the INCY balance sheet.
- INCY's operating cash flow of $1.25B allows it to safely service it's debt of $35.37M.
- INCY profit margin has gone up from 0.8% to 24.7% in the past year.
- INCY has a low debt to equity ratio of 0.36.
- INCY earnings of $1.59B is not enough to cover its interest payments.
- There are more short-term assets than long-term liabilities on the INCY balance sheet.
Is it a good time to buy INCY stock, according to analysts?
Out of 13 Equities analysts who give forecasts on INCY, the consensus analyst rating on INCY is a Buy
Please keep in mind that analyst ratings are not recommendations, nor are they investment advice.
Most Recent INCY Analyst Recommendations
Allison Bratzel, a top 8% analyst from Piper Sandler maintains INCY with a strong buy rating and raises their INCY price target from $82.00 to $102.00, on Nov 4, 2025.
Piper Sandler's Allison Bratzel raised their price target on Incyte (NASDAQ: INCY) by 24.4% from $82 to $102 on 2025/11/04. The analyst maintained their Strong Buy rating on the stock.
Incyte reported its Q3 2025 earnings.
Bratzel detailed from the quarter's "strong" results that Jakafi posted a $20M beat and Opzelura $11M beat.
Further, the analyst said, non-GAAP EPS of $2.26 represented $0.63 in upside against consensus.
Bratzel declared themselves a "buyer" because the stock's risk/reward remains favorable at current levels, given Incyte's continued commercial momentum, key leadership changes, strategic partnerships, and pipeline prioritizations.
Earnings Report
For Q3 2025, Incyte reported:
- EPS of $2.26, which beat the Zacks Consensus Estimate of $1.66 and, by 111.2%, Q3 2024’s $1.07.
- Revenue of $1.37B, which beat the Zacks Consensus Estimate by 8.71% and, by 20%, Q3 2024’s $1.14B.
For FY 2025, management guided:
- Revenue of $4.23B to $4.32B.
President & CEO Bill Meury commented: “Our Q3 results demonstrate strong growth across our product portfolio, with net product revenues increasing 19% Y/Y, which highlights the momentum in our business and effective commercial execution.
“We are taking a deliberate approach to pipeline prioritization.
“We are actively reviewing our R&D efforts and focusing on high-value programs that are scientifically differentiated, address unmet medical needs, and have the potential to significantly drive Incyte’s next phase of growth."
Michael Schmidt, a top 2% analyst from Guggenheim upgrades INCY to a strong buy rating and announces their INCY price target of $125.00, on Nov 3, 2025.
Brian Abrahams, a top 16% analyst from RBC Capital maintains INCY with a hold rating and raises their INCY price target from $81.00 to $84.00, on Oct 29, 2025.
Srikripa Devarakonda, a top 15% analyst from Truist Securities reiterates INCY with a hold rating and raises their INCY price target from $79.00 to $93.00, on Oct 29, 2025.
Peter Lawson, a bottom 6% analyst from Barclays maintains INCY with a strong buy rating and raises their INCY price target from $90.00 to $101.00, on Oct 29, 2025.
You can dive deeper into what analysts are projecting on the Incyte stock forecast page.
INCY Technical Indicators
INCY Growth Metrics
Last year, INCY earnings were $1.19B. During the past four year, INCY's earnings have gone up by 25.56% per year. This was faster than the Biotechnology industry average of 10.24%.
Last year, INCY revenue was $4.81B. In the last 5 year, INCY's revenue has increased by 14.4% per year. This was slower than the Biotechnology industry average of 43.3%.
Dig into INCY's earnings and revenue performance here.
Who is buying/selling INCY?
Over the past 12 months, insiders at INCY have sold more shares than they have bought.
Lee Heeson, EVP Head of Incyte Intl of INCY, was the latest INCY insider to sell. They sold $11,396.37 worth of INCY shares on Feb 2, 2026.
Get more info about who owns INCY shares here.
Does INCY provide a stable income stream?
No, Incyte doesn't provide an income stream by paying out dividends.
What others are saying about INCY
One of the major reasons eToro is our favorite brokerage is because of its social trading community.
Click below to learn what other community members have to say.
Step 5: Execute your INCY purchase
There are two main options:
- Market order: A market order is an order to buy or sell a security at the best possible price.
Market orders are usually the easiest way to buy. - Limit order: A limit order allows you to buy or sell a stock at a specific price (or better).
If you want to be sure you're buying or selling at a specific price, use a limit order.
Click the Open button and eToro will place your order.
If you want more help buying stocks on eToro, watch the how to video below:
Step 6: Monitor your INCY position
Now that you own some shares in INCY, you'll want to keep up with your new shares.
Make a watchlist to track the latest developments regarding your INCY stock.
INCY Feed
How to Buy Stock in Incyte
To summarize, here are the 6 steps you need to take to buy Incyte stock right now:
- Figure out where to buy Incyte stock
- Sign up for your brokerage account
- Deposit funds into your brokerage account
- Analyze Incyte stock
- Execute your INCY purchase
- Monitor your INCY position
If you require a online brokerage, eToro is our recommended venue.
Get Started with eToro TodayIf you would like to track your new investment in Incyte, create a watchlist today.
Other Content You Might Find Useful
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.